Skip to content

    Publications

    Review select publications related to our three translational research projects and the Biospecimen and Pathology Core. 

    Project 1: Developing a Diagnostic Test and Therapeutic Agents for Fibrolamellar Hepatocellular Carcinoma

    2024

    Increased protein kinase A activity induces fibrolamellar hepatocellular carcinoma features independent of DNAJB1

    Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma

    GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma

    2023

    Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma

    Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma

    Oncogenic addiction of Fibrolamellar hepatocellular carcinoma to the fusion kinase DNAJB1-PRKACA

    Alternative lengthening of telomeres in primary hepatic neoplasms

    2022

    Clinical and demographic predictors of survival for fibrolamellar carcinoma patients-A patient community, registry-based study

    Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

    Targeting BCL-XL in fibrolamellar hepatocellular carcinoma

    Human liver organoids for disease modeling of fibrolamellar carcinoma

    2021

    Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient¬Derived Xenografts and Direct-from-Patient Screening

    Morphologic and Molecular Findings in Myxoid Hepatic Adenomas

    Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A

    2020

    Structural analyses of the PKA Rllf3 holoenzyme containing the oncogenic DnaJB1-PKAc fusion protein reveal protomer asymmetry and fusion-induced allosteric perturbations in fibrolamellar hepatocellular carcinoma

    Stem cell-derived polarized hepatocytes

    A Human Organoid Model of Aggressive Hepatoblastoma for Disease Modeling and Drug Testing

    2019

    Structures of the PKA Ria Holoenzyme with the FLHCC Driver J-PKAca or Wild-Type PKAca

    2018

    Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion

    Sequencing the peripheral blood B and T cell repertoire - Quantifying robustness and limitations

    Non coding RNA analysis in fibrolamellar hepatocellular carcinoma

    Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms

    Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma

    Intracranial metastasis in fibrolamellar hepatocellular carcinoma

    Project 2: Therapeutic Inhibition of Fibroblast Growth Factor and YAP Signaling in Cholangiocarcinoma

    2024

    Metabolomics Utilized by Machine Learning Approaches Can Classify Cholangiocarcinoma Patients from Normal Controls JHEP Reports [under revision-publication pending]

    YAPTEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape Mol Oncology [submitted-publication pending]

    2023

    LCK inhibtion downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

    2022

    Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy

    2021

    FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

    2020

    The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies

    The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma

    2019

    YAP and the Hippo pathway in cholangiocarcinoma

    Project 3: Development of a New Viral Immunotherapeutic Approach for Hepatocellular Carcinoma

    2023

    Oncolytic viruses: Narcissistic or altruistic arsonists?

    Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses

    2022

    Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

    2021

    Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy

    APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable

    Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?

    Oncolytic virotherapy as immunotherapy

    ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome

    2020

    Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers

    Biospecimen and Pathology Core

    2024

    Genome-wide DNA methylation markers associated with metabolic liver cancer

    Join the fight against cancer!

    Give Now

    Make a gift to our 2025 Drive to Cure Cancer and transform the way cancer is treated and defeated.

    Give Now

    Unknown Component Type: core/wcm/components/image/v3/image